Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease
(PD), and the central blockade of adenosine A1 receptor improves cognitive function. In the …

Adenosine A2A antagonists are believed to have therapeutic potential in the treatment of
Parkinson's disease (PD). We have characterized the dual adenosine A2A/A1 receptor …

The in vivo characterization of a dual adenosine A2A/A1 receptor antagonist in several
animal models of Parkinson's disease is described. Discovery and scale-up syntheses of …

Adenosine A2A receptor antagonists have emerged as an attractive non-dopaminergic
target in clinical trials aimed at evaluating improvement in motor deficits in Parkinson's …

4-Acetylamino-2-(3, 5-dimethylpyrazol-1-yl)-pyrimidines bearing substituted pyridyl groups
as C-6 substituents were prepared as selective adenosine hA2A receptor antagonists for the …

A novel adenosine A2A receptor selective antagonist, KW-6002 [(E)-1, 3-diethyl-8-(3, 4-
dimethoxystyryl)-7-methyl-3, 7-dihydro-1H-purine-2, 6-dione], possesses antiparkinsonian …

Abstract Rationale: Current treatment of Parkinson's disease (PD) is based on dopamine
replacement therapy, but this leads to long term complications, including dyskinesia …

Recent evidence indicates that adenosine A2A receptor antagonists hold therapeutic
potential for the treatment of Parkinson's disease (PD). A study on the novel adenosine A1 …

Adenosine A1 receptors in the brain are believed to play an important role in brain
functioning. We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1 …

The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in
several animal models of Parkinson's disease is described. Compound 1 was previously …